Isofol Medical AB (ISOFOL) AI Stock Analysis

• Market Cap: kr187.92M
• Dividend Yield: N/A
• Average Volume (3M): 501.89K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.53
• Revenue Growth: N/A
• EPS Growth: -34.02%
• Country: SE
• Employees: 5
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.05
• Shares Outstanding: 281,107,240
• 10 Day Avg. Volume: 847,726
• 30 Day Avg. Volume: 501,890
• PEG Ratio: -0.47
• Price to Book (P/B): 4.59
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -8.52
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: kr0.69 ▼(-4.58% Downside)

The score is driven primarily by weak financial performance (no revenue, ongoing losses, and sustained cash burn), partially mitigated by a low-debt, solvent balance sheet. Technicals are mildly bearish with neutral momentum, and valuation is constrained by negative earnings and lack of dividend support.

Positive Factors

Intellectual Property Strength

Securing a long-term patent strengthens Isofol's competitive position and supports sustained development and commercialization efforts.

Clinical Progress

Advancing clinical trials with positive results enhances the potential for regulatory approval and market entry, crucial for long-term growth.

Strong Balance Sheet

A strong balance sheet with low debt provides financial stability and flexibility, supporting ongoing R&D and operational needs.

Negative Factors

Lack of Revenue

The absence of revenue generation increases financial risk and dependency on external funding, challenging long-term sustainability.

Cash Burn

High cash burn rates necessitate ongoing funding, posing risks to financial health and potentially diluting shareholder value over time.

Earnings Volatility

Continued losses and earnings volatility reflect the challenges of a development-stage biotech, impacting investor confidence and valuation.

Isofol Medical AB Business Overview & Revenue Model

Company Description

Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska University Hospital. The company was incorporated in 2008 and is headquartered in Gothenburg, Sweden.

How the Company Makes Money

Isofol Medical AB generates revenue primarily through the development and commercialization of its lead product, arfolitixorin. Revenue streams include licensing agreements, collaborations with pharmaceutical companies, and potential sales upon regulatory approval. The company engages in strategic partnerships to facilitate research, development, and distribution, which contribute to its earnings. Additionally, Isofol may receive milestone payments and royalties from partner collaborations, further supporting its financial model. The company's focus on oncology treatments positions it to benefit from the growing demand for cancer therapies globally.

Isofol Medical AB Financial Statement Overview

Summary

Income statement and cash flow are very weak with zero revenue, persistent losses, and consistently negative operating/free cash flow (TTM FCF ~-48.8M). The main offset is a conservatively levered balance sheet with essentially no debt and positive equity, but ongoing cash burn and lack of revenue keep financial risk elevated.

Income Statement

The company remains in a heavy loss-making phase with no meaningful revenue contribution in the most recent periods (revenue is 0 in 2024 annual and TTM (Trailing-Twelve-Months)). Losses have narrowed materially versus 2020–2022 (net loss improved from about -189.0M in 2020 and -159.8M in 2022 to -43.5M in 2024), indicating cost rationalization, but profitability is still far from breakeven. Margins are not informative recently due to zero revenue, and historical margins were deeply negative, reflecting a development-stage biotech profile and continued earnings volatility.

Balance Sheet

The balance sheet is conservatively levered with essentially no debt (0 debt in 2023–TTM; very small debt in earlier years), which reduces financial risk. Equity remains positive and sizable relative to assets (TTM equity ~120.6M vs. assets ~142.1M), supporting solvency. The key weakness is ongoing value erosion from losses (return on equity remains strongly negative, including TTM), and equity has fluctuated meaningfully over time, implying continued dependence on funding and/or periodic capital raises to sustain operations.

Cash Flow

Cash generation is a clear weak point: operating cash flow and free cash flow are consistently negative across all periods (TTM operating/free cash flow ~-48.8M; 2024 ~-42.0M). While cash burn is far lower than 2020–2022 levels (when annual operating cash outflows were ~-160M to -191M), TTM free cash flow deteriorated versus 2024 (negative growth in TTM), signaling burn can re-accelerate. Cash flow roughly tracks accounting losses (free cash flow to net income ~1.0), which is typical for R&D-heavy businesses but still highlights sustained funding needs.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	721.00K	12.80M	22.41M	37.12M
Gross Profit	-31.55M	-38.73M	-34.41M	-165.71M	-174.31M	-162.42M
EBITDA	-54.49M	-47.21M	-37.02M	-159.73M	-198.49M	-187.07M
Net Income	-54.49M	-43.49M	-37.07M	-159.79M	-200.25M	-188.99M
Balance Sheet
Total Assets	142.13M	98.42M	140.60M	213.46M	401.36M	148.13M
Cash, Cash Equivalents and Short-Term Investments	138.79M	96.16M	138.15M	190.58M	379.45M	116.39M
Total Debt	0.00	0.00	0.00	3.95M	1.65M	3.12M
Total Liabilities	21.51M	20.47M	19.16M	54.99M	83.13M	81.56M
Stockholders Equity	120.62M	77.94M	121.43M	158.48M	318.23M	66.57M
Cash Flow
Free Cash Flow	-48.84M	-41.99M	-52.54M	-190.97M	-188.43M	-160.27M
Operating Cash Flow	-48.84M	-41.99M	-52.54M	-190.97M	-188.43M	-160.27M
Investing Cash Flow	0.00	0.00	101.00K	0.00	0.00	1.00K
Financing Cash Flow	84.07M	0.00	0.00	23.00K	450.48M	150.01M

Isofol Medical AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.72
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ISOFOL, the sentiment is Negative. The current price of 0.72 is above the 20-day moving average (MA) of 0.71, above the 50-day MA of 0.71, and below the 200-day MA of 0.90, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 40.44 is Neutral, neither overbought nor oversold. The STOCH value of 27.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ISOFOL.

Isofol Medical AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XINT	49 Neutral	kr253.21M	-4.59	―	―	-7.68%	17.93%
IRLAB.A	46 Neutral	kr153.91M	-1.15	-199.86%	―	69.03%	23.10%
ISOFOL	44 Neutral	kr187.92M	-2.33	-51.35%	―	―	-34.02%
MODTX	43 Neutral	kr37.70M	-1.37	-166.94%	―	―	-19.35%
ACTI	41 Neutral	kr109.66M	-1.29	-1291.15%	―	―	28.54%

Isofol Medical AB Corporate Events

Isofol Showcases Arfolitixorin Trial Design at ASCO GI as Phase Ib/II Study Advances

Isofol Medical AB will participate in the ASCO GI Cancer Symposium in San Francisco, where it will present a Trial in Progress abstract outlining the design and recruitment status of its ongoing phase Ib/II study of arfolitixorin in metastatic colorectal cancer. The study, conducted at Charité – Universitätsmedizin Berlin, tests a new dosing regimen and escalating doses of arfolitixorin in combination with 5-FU chemotherapy, oxaliplatin and bevacizumab as first-line treatment, underscoring the candidate’s potential to address a significant treatment gap in one of the world’s most common and deadly cancers. Company executives describe the congress appearance and planned advisory-board meetings as an important start to the year, as Isofol aims to complete the first part of the trial and move into phase II, a step that could prove pivotal for its clinical development program and its positioning in colorectal cancer therapeutics.

The most recent analyst rating on (SE:ISOFOL) stock is a Hold with a SEK0.69 price target. To see the full list of analyst forecasts on Isofol Medical AB stock, see the SE:ISOFOL Stock Forecast page.

Isofol Medical to Showcase Arfolitixorin at Upcoming Investor Meetings

Isofol Medical AB announced its participation in several investor meetings in December and January to present its drug candidate, arfolitixorin. This drug is currently in a phase Ib/II clinical study and has the potential to address a significant treatment gap in cancer care. The company’s CEO, Petter Segelman Lindqvist, will present at various events, highlighting the drug’s potential impact on cancer treatment.

Isofol Medical Secures New Patent for Cancer Drug Candidate Arfolitixorin

Isofol Medical AB announced that the European Patent Office intends to grant a new product patent for its cancer drug candidate, arfolitixorin, which will provide protection until 2043. This patent strengthens Isofol’s intellectual property portfolio, supporting the long-term development and commercialization of arfolitixorin, and increases the project’s value. The patent will cover pharmaceutical compositions comprising arfolitixorin in stable lyophilizate form, and the company plans to pursue additional patent protection in key regions such as the US and Japan.

Isofol Medical AB Reports Key Developments in Interim Report

Isofol Medical AB has released its interim report for January to September 2025, highlighting significant financial and operational developments. Despite reporting no net revenue and a negative result for the period, the company successfully completed a rights issue, raising approximately SEK 84 million. Key milestones include a successful pre-IND meeting with the FDA and progress in their clinical phase Ib/II study of arfolitixorin, which has been well tolerated at the second dose level. These developments underscore Isofol’s commitment to advancing its drug candidate for colorectal cancer treatment.

Isofol Medical AB Appoints Nomination Committee for 2026 AGM

Isofol Medical AB has appointed a nomination committee for its 2026 Annual General Meeting, following the principles established in the 2025 meeting. The committee consists of representatives from the company’s largest shareholders, collectively holding approximately 23.72% of the shares and votes. This strategic move is part of Isofol’s governance process, potentially impacting its future leadership and strategic decisions.

Isofol Medical AB to Host Investor Meeting on Arfolitixorin Progress

Isofol Medical AB announced an investor meeting to update stakeholders on the progress of their drug candidate, arfolitixorin, which is undergoing a phase Ib/II clinical study at Charité – Universitätsmedizin Berlin. This meeting, scheduled for November 13, 2025, will provide insights into the potential of arfolitixorin to address treatment gaps in cancer care, with opportunities for participants to engage in discussions both in-person and online.

Isofol Medical AB to Present at ESMO Cancer Congress

Isofol Medical AB announced its participation in the ESMO cancer congress in Berlin, where it will present an abstract on its ongoing phase Ib/II study of arfolitixorin. This study, conducted in collaboration with Charité – Universitätsmedizin Berlin, explores a new dosage regimen for arfolitixorin in combination with standard chemotherapy for metastatic colorectal cancer. The participation in ESMO is expected to enhance Isofol’s visibility and strengthen its scientific network, as the company aims to address the urgent need for improved colorectal cancer treatments.